NCT02321878 - Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®) | Biotech Hunter

Enrollment

1,092

Participants

Timeline

Start Date

December 15, 2014

Primary Completion Date

June 16, 2017

Study Completion Date

June 16, 2017

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."

Trial Locations (5)

Novo Nordisk Investigational Site, Tokyo

Novo Nordisk Investigational Site, Chichibu

Novo Nordisk Investigational Site, Koriyama-shi, Fukushima

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

Novo Nordisk Investigational Site, Tagajō-shi